Focus on Anticoagulation Care

Back to articles

MAGELLAN: Rivaroxaban reduces venous thromboembolism risk in hospitalized patients


In individuals hospitalized for acute medical illness, thromboprophylaxis with rivaroxaban (Xarelto—Bayer, Ortho–McNeil Janssen) was noninferior to enoxaparin at 10 days, according to a recent study. At 35 days, rivaroxaban was superior to 10 days of enoxaparin followed by 25 days of placebo. Rivaroxaban was associated with increased bleeding risk.


Cohen AT et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.